Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

Several other equities research analysts also recently issued reports on MBRX. Maxim Group cut their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a research report on Tuesday, March 26th. Roth Mkm reiterated a buy rating and issued a $40.00 price target on shares of Moleculin Biotech in a research report on Friday, April 12th.

Moleculin Biotech Stock Up 7.0 %

Shares of MBRX stock opened at $4.60 on Friday. The firm has a 50 day moving average price of $6.87 and a two-hundred day moving average price of $8.08. The company has a market capitalization of $10.26 million, a PE ratio of -0.34 and a beta of 1.96. Moleculin Biotech has a 12-month low of $4.28 and a 12-month high of $15.75.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Atticus Wealth Management LLC purchased a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned approximately 0.17% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.